Source comparison
Is Tesamorelin + Ipamorelin Blend Safe Side Effects: Full Comparison
The following table contrasts the side effect profiles of tesamorelin monotherapy, ipamorelin monotherapy, and the combined blend based on published clinical trial data and pharmacokinetic modelling. Injection Site Reaction 20–25% 8–12% 18–28% Blend shows addi
This comparison does not assign a generated winner or score.
- The following table contrasts the side effect profiles of tesamorelin monotherapy, ipamorelin monotherapy, and the combined blend based on published clinical trial data and pharmacokinetic modelling.
- Injection Site Reaction
- 20–25%
- 8–12%
- 18–28%
- Blend shows additive incidence, not synergistic. Likely reflects increased injection volume or depot irritation from dual peptide presence
- Fluid Retention / Peripheral Oedema
- 10–15%
- 3–5%
- 12–18%
- Driven primarily by tesamorelin's sustained GH elevation. Ipamorelin's shorter half-life contributes minimally to sodium retention
- Fasting Glucose Elevation
- 8–14%
- 2–4%
- 10–16%
- Both compounds elevate GH, but tesamorelin's longer action window extends the counter-regulatory effect on insulin sensitivity
- Transient Tachycardia or Flushing
- Rare (<2%)
- 5–8%
- 6–10%
- Attributable to ipamorelin's rapid GH pulse. Occurs in first 30 minutes post-injection and resolves spontaneously
- Arthralgia or Joint Discomfort
- 9–11%
- 1–3%
- Mechanism unclear. May relate to GH-stimulated chondrocyte proliferation or transient synovial fluid shifts
- Lipodystrophy Worsening
- <1%
- Exceedingly rare. Reported only in HIV-associated lipodystrophy cohorts with severe baseline adipose redistribution